Tekturna Label Changes, Valturna Market Withdrawal Announced by Novartis
Novartis announced yesterday that the label for the blood pressure drug Tekturna (aliskiren) will be updated with new warnings regarding its use in people with diabetes and kidney problems. Novartis also announced it will no longer market Valturna, a single-pill combination of aliskiren and the ARB valsartan. According to a … [Read more...]
Tekturna (Aliskiren) Associated with Serious Side Effects, Including Stroke, Severe Kidney Damage
Tekturna (aliskiren) and other medications containing aliskiren have been associated with serious side effects, including non-fatal stroke and severe kidney damage, in some patients. Tekturna and other aliskiren products were recently the subject of safety warnings in Europe (where it is sold as Rasilez), and Novartis has updated … [Read more...]